Patient Preferences for the Treatment of ER+/HER2- Metastatic Breast Cancer: A Discrete Choice Experiment

Speaker(s)

Smith ML1, Swallow E2, Cook E2, Wang Y2, Akbarnejad H2, Tamakloe K2, Pelletier C3, Bergman R4, Kreup E4, Rao R5
1Research Advocacy Network, Plano, TX, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Menarini Group, East Rutherford, NJ, USA, 4Menarini Group, New York, NY, USA, 5Rush University Cancer Center, Chicago, IL, USA

Presentation Documents

OBJECTIVES: To assess patient preferences for specific attributes of ER+/HER2- metastatic breast cancer (mBC) treatments.

METHODS: An online discrete choice experiment (DCE) and survey were conducted in March-April 2024. Eligible participants included US adults with self-reported ER+/HER2- mBC. Attributes related to efficacy (time on treatment while disease remains stable before worsening), adverse events (risk of nausea, rash, severe diarrhea), risk of treatment discontinuation due to side effects, treatment administration (daily oral, monthly injections, daily oral + monthly injections), and whether the treatment is targeted towards a mutation were included. Participants were presented with 14 choice tasks in which they were asked to select one of two hypothetical treatment profiles. A mixed logistic regression model was used to determine relative patient preferences for attributes.

RESULTS: 165 patients completed the survey, 100% female, mean age was 48 years. Approximately 75% of patients received ≥2 treatment regimens. The most important treatment attributes identified were efficacy, defined as time on treatment while disease remains stable before worsening (45%), followed by being a mutation-specific treatment (15%). Regarding safety and tolerability, the risk of severe rash (11%) was considered more important than the risk of severe diarrhea (8%), nausea (7%) and discontinuation due to side effects (7%). Administration favored daily oral and monthly injectable treatments over the combination (8%). Most patients (63%) agreed that infusion and injection treatments were larger reminders of mBC than oral treatments. Fewer patients (39%) indicated that treatment frequency impacts on their level of worry.

CONCLUSIONS: Understanding patient preferences may help improve treatment decisions. For the ER+/HER2- mBC patients surveyed in this DCE, the most valued treatment attributes were efficacy defined as time on treatment while disease remains stable before worsening (PFS), being targeted to a specific mutation followed by a manageable and tolerable safety profile and a convenient route of administration.

Code

PCR236

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Oncology